Skip links

Dr Carlo Brigouri Talks About RenalGuard REMEDIAL III Trial

Interview by Dr C. Michael Gibson at TCT2019 in San Francisco

Following the publication of the REMEDIAL III trial results and their presentation at TCT2019 in San Francisco, Dr Carlo Brigouri spoke with Dr C. Michael Gibson at the Congress to explain the work his team undertook.

Link to video of Dr Carlo BrigouriThe 700 patient, randomised, investigator-driven REMEDIAL III trial found that RenalGuard Therapy® is superior to the POSEIDON method in preventing contrast-induced acute kidney injury (CI-AKI) for patients with kidney disease who undergo interventional procedures.


Clinicians interested in discussing the benefits of RenalGuard Therapy for their patients should contact Murat Celebi, Clinical Marketing Director, on +44 (0)1234-888955 or by email via